AB136
Anti-Dopa Decarboxylase Antibody
Chemicon®, from rabbit
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
UNSPSC-Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Empfohlene Produkte
Biologische Quelle
rabbit
Qualitätsniveau
Antikörperform
affinity isolated antibody
Antikörper-Produkttyp
primary antibodies
Klon
polyclonal
Aufgereinigt durch
affinity chromatography
Speziesreaktivität
canine, sheep, human
Hersteller/Markenname
Chemicon®
Methode(n)
western blot: suitable
NCBI-Hinterlegungsnummer
UniProt-Hinterlegungsnummer
Versandbedingung
wet ice
Posttranslationale Modifikation Target
unmodified
Angaben zum Gen
human ... DDC(1644)
Spezifität
DOPA Decarboxylase (DDC). Reacts with a single band of ~55 kDa by Western blot. Reacts best with human samples; reactivity low with rodent and rabbit species.
Immunogen
Synthetic peptide from the N-terminal region of human DDC conjugated to KLH.
Anwendung
Research Category
Neurowissenschaft
Neurowissenschaft
Research Sub Category
Neurotransmitter & Rezeptoren
Neuronen- & Gliamarker
Neurotransmitter & Rezeptoren
Neuronen- & Gliamarker
Anti-Dopa Decarboxylase Antibody is an antibody against Dopa Decarboxylase for use in WB.
Immunoblotting: 1:1000
Optimal working dilutions must be determined by the end user.
Optimal working dilutions must be determined by the end user.
Physikalische Form
Affinity-purified antibody. Liquid in 10 mM HEPES, pH 7.5, 150 mM NaCl, 100 μg/mL BSA and 50% glycerol.
Lagerung und Haltbarkeit
Maintain at -20 to -80°C in undiluted aliquots for up to six months after date of receipt. Store in a non-self-defrosting freezer. Avoid repeated freeze-thaw cycles.
Rechtliche Hinweise
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Haftungsausschluss
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Sie haben nicht das passende Produkt gefunden?
Probieren Sie unser Produkt-Auswahlhilfe. aus.
Lagerklassenschlüssel
10 - Combustible liquids
WGK
WGK 1
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury.
Yang, S; Yao, B; Zhou, Y; Yin, H; Zhang, MZ; Harris, RC
American Journal of Physiology: Renal Physiology null
Thamara E Osinga et al.
Neuroendocrinology, 101(4), 289-295 (2015-02-14)
Increased dopamine production may be a feature of head and neck paraganglioma (HNPGL). 18F-fluorodihydroxyphenylalanine positron emission tomography scintigraphy has a high sensitivity for detecting HNPGLs. These observations strongly suggest that HNPGLs have the capacity for L-3,4-dihydroxyphenylalanine uptake and conversion towards
Mohammad M Doroudchi et al.
Journal of neurochemistry, 93(3), 634-640 (2005-04-20)
Although L-DOPA is the drug of choice for Parkinson's disease, prolonged L-DOPA therapy results in decreased drug effectiveness and the appearance of motor complications. This may be due in part to the progressive loss of the enzyme, aromatic L-amino acid
Agnieszka Ciesielska et al.
PloS one, 10(4), e0122708-e0122708 (2015-04-11)
Progressively blunted response to L-DOPA in Parkinson's disease (PD) is a critical factor that complicates long-term pharmacotherapy in view of the central importance of this drug in management of the PD-related motor disturbance. This phenomenon is likely due to progressive
Annika M A Berends et al.
European journal of endocrinology, 179(2), 125-133 (2018-06-08)
PET with 6-[18F]fluor-l-3,4-dihydroxyphenylalanine (18F-FDOPA) has been shown to be a useful imaging tool with a high sensitivity for the visualization of neuroendocrine tumors (NETs). 18F-FDOPA uptake in tumors other than NETs has been suggested previously, but data on this phenomenon
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.